Salicylic acid: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 27: Line 27:
* Removal of wart
* Removal of wart
:* Apply TOPICALLY once or twice daily in concentrations of 5% to 40% for up to 12 weeks
:* Apply TOPICALLY once or twice daily in concentrations of 5% to 40% for up to 12 weeks
|offLabelAdultNoGuideSupport======Condition1=====
|offLabelAdultNoGuideSupport=


* Dosing Information
:* Dosage
=====Condition2=====


There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
Line 40: Line 35:


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
|fdaLIADPed=
 
* Dosing Information
 
:* Dosage


=====Condition2=====


There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
Line 53: Line 43:


<!--Guideline-Supported Use (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
|offLabelPedGuideSupport=
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
|offLabelPedNoGuideSupport=
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Contraindications-->
<!--Contraindications-->
|contraindications=* Condition1
<!--Warnings-->
|warnings=* For external use only.
|warnings=* For external use only.
* Avoid contact with eyes. If contact occurs, rinse thoroughly with water.
* Avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Line 90: Line 57:
* Do not use for prolonged periods without consulting a doctor.
* Do not use for prolonged periods without consulting a doctor.
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
Line 113: Line 76:
|administration=* Oral
|administration=* Oral


* Intravenous
 
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.


* Description
 


<!--IV Compatibility-->
<!--IV Compatibility-->
Line 122: Line 85:


<!--Overdosage-->
<!--Overdosage-->
|overdose====Acute Overdose===
|overdose=There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.


<!--Pharmacology-->
<!--Pharmacology-->


<!--Drug box 2-->
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|drugBox={{chembox2
|mechAction=*
| Watchedfields = changed
| verifiedrevid = 477314005
| Name = Salicylic acid
| ImageFileL1 = Salicylic-acid-skeletal.svg
| ImageSizeL1 = 100px
| ImageNameL1 = Skeletal formula of salicylic acid
| ImageFileR1 = Salicylic-acid-from-xtal-2006-3D-balls.png
| ImageSizeR1 = 100px
| ImageNameR1 = Ball-and-stick model of salicylic acid
| ImageFile2 = Kwas salicylowy.jpg
| ImageSize2 = 200px
| ImageName2 = Salicylic acid
| IUPACName = 2-Hydroxybenzoic acid
| Section1 = {{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = O414PZ4LPZ
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00097
| InChI = 1/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)
| InChIKey = YGSDEFSMJLZEOE-UHFFFAOYAQ
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 424
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YGSDEFSMJLZEOE-UHFFFAOYSA-N
| CASNo = 69-72-7
| CASNo_Ref = {{cascite|correct|CAS}}
| PubChem = 338
| EINECS = 200-712-3
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 331
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00936
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 16914
| SMILES = c1ccc(c(c1)C(=O)O)O
| ATCCode_prefix = A01
| ATCCode_suffix = AD05
| ATC_Supplemental = {{ATC|B01|AC06}} {{ATC|D01|AE12}} {{ATC|N02|BA01}} {{ATC|S01|BC08}}
| RTECS = VO0525000
}}
| Section2 = {{Chembox Properties
| C=7|H=6|O=3
| Appearance = colorless to white crystals
| Odor = odorless
| MeltingPtC = 158.6
| BoilingPtC = 200
| Boiling_notes = <br> decomposes<ref name=chemister /><br> {{convert|211|C|F K}}<br> at 20 mmHg<ref name=crc>{{RubberBible92nd|page=3.306}}</ref>
| pKa = 1 = 2.97 (25 °C)<ref>[http://www.drugbank.ca/drugs/DB00936 Salicyclic acid]. Drugbank.ca. Retrieved on 2012-06-03.</ref><br> 2 = 13.82 (20 °C)<ref name=chemister />
| Density = 1.443 g/cm<sup>3</sup> (20 °C)<ref name=crc/>
| Solubility = 1.24 g/L (0 °C)<br> 2.48 g/L (25 °C)<br> 4.14 g/L (40 °C)<br> 17.41 g/L (75 °C)<ref name=chemister>http://chemister.ru/Database/properties-en.php?dbid=1&id=1777</ref><br> 77.79 g/L (100 °C)<ref name=sioc>{{cite book|last = Seidell|first = Atherton|last2 = Linke|first2 = William F.|year = 1952|title = Solubilities of Inorganic and Organic Compounds|publisher = Van Nostrand|url = [http://books.google.com/books?id=k2e5AAAAIAAJ Google Books]|accessdate = 2014-05-29}}</ref>
| SolubleOther = soluble in [[ether]], [[carbon tetrachloride|CCl<sub>4</sub>]], [[benzene]], [[propanol]], [[acetone]], [[ethanol]], [[oil of turpentine]], [[toluene]]
| Solubility1 = 0.46 g/100 g (11.7 °C)<br> 0.775 g/100 g (25 °C)<br> 0.991 g/100 g (30.5 °C)<br> 2.38 g/100 g (49.4 °C)<br> 4.4 g/100 g (64.2 °C)<ref name=chemister /><ref name=sioc />
| Solvent1 = benzene
| Solubility2 = 2.22 g/100 mL (25 °C)<ref name=sioc /><br> 2.31 g/100 mL (30.5 °C)<ref name=chemister />
| Solvent2 = chloroform
| Solubility3 = 40.67 g/100 g (−3 °C)<br> 62.48 g/100 g (21 °C)<ref name=chemister />
| Solvent3 = methanol
| Solubility4 = 2.43 g/100 g (23 °C)<ref name=chemister />
| Solvent4 = olive oil
| Solubility5 = 39.6 g/100 g (23 °C)<ref name=chemister />
| Solvent5 = acetone
| RefractIndex = 1.565 (20 °C)<ref name=crc/>
| LogP = 2.26
| VaporPressure = 10.93 mPa<ref name=pubchem>{{PubChemLink|338}}</ref>
| SublimationConditions = sublimes at 76 °C<ref name=pubchem />
| LambdaMax = 210 nm, 234 nm, 303 nm (4&nbsp;mg % in ethanol)<ref name=pubchem />
}}
|mechAction=  
Salicylic acid has been shown to work through several different pathways. It produces its anti-inflammatory effects via suppressing the activity of cyclooxygenase (COX), an enzyme that is responsible for the production of pro-inflammatory mediators such as the prostaglandins. It does this not by direct inhibition of COX like most other non-steroidal anti-inflammatory drugs (NSAIDs) but instead by suppression of the expression of the enzyme (via a yet-unelucidated mechanism).<ref name=Science connections>{{cite web | title = American chemical society | url =http://www.cas.org/news/insights/science-connections/aspirin }}</ref> Salicylic acid has also been shown to activate adenosine monophosphate-activated protein kinase (AMPK), and it is thought that this action may play a role in the anticancer effects of the compound and its prodrugs aspirin and salsalate. In addition, the antidiabetic effects of salicylic acid are likely mediated by AMPK activation primarily through allosteric conformational change that increases levels of phosphorylation.<ref name="pmidPMID 22517326">{{cite journal| author=Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ et al.| title=The ancient drug salicylate directly activates AMP-activated protein kinase. | journal=Science | year= 2012 | volume= 336 | issue= 6083 | pages= 918-22 | pmid=PMID 22517326 | doi=10.1126/science.1215327 | pmc=PMC3399766 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22517326  }} </ref> Salicylic acid also uncouples oxidative phosphorylation, which leads to increased ADP:ATP and AMP:ATP ratios in the cell. As a consequence, salicylic acid may alter AMPK activity and subsequently exert its anti-diabetic properties through altered energy status of the cell. Even in AMPK knock-out mice, however, there is an anti-diabetic effect, demonstrating that there is at least one additional, yet-unidentified action of the compound.<ref name=New Scientist>{{cite web | title = New scientist | url =http://www.newscientist.com/article/dn21718-clues-to-aspirins-anticancer-effects-revealed.html#.VJEfNyvF_Mc }}</ref>
 
|structure=


<!--Structure-->
|structure=*


: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]


<!--Pharmacodynamics-->
<!--Pharmacodynamics-->
Line 168: Line 188:
<!--Brand Names-->
<!--Brand Names-->
|brandNames=* ALA-SEPTIC®<ref>{{Cite web | title =ALA-SEPTIC- salicylic acid cream  | url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edb70750-bea8-4c0f-9453-f2c38d2f05d9  }}</ref>
|brandNames=* ALA-SEPTIC®<ref>{{Cite web | title =ALA-SEPTIC- salicylic acid cream  | url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=edb70750-bea8-4c0f-9453-f2c38d2f05d9  }}</ref>
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>


Revision as of 06:17, 17 December 2014

{{DrugProjectFormSinglePage |authorTag=Ammu Susheela, M.D. [1] |genericName=Salicylic acid |aOrAn=a |drugClass=anti acne agent |indicationType=treatment |indication=acne, for relief of itching, irritation, redness and scaling assoicated with psoriasis, eczema and seborrheic dermatitis |adverseReactions=hypersensitivity reaction, salicylate toxicity |blackBoxWarningTitle=ConditionName: |blackBoxWarningBody=ConditionName:

  • Content


|fdaLIADAdult=* FOR THE TREATMENT OF ACNE

  • HELPS KEEP SKIN CLEAR OF NEW ACNE BLEMISHES
  • For relief of itching, irritation, redness and scaling assoicated with psoriasis, eczema and seborrheic dermatitis.

|offLabelAdultGuideSupport=* Acne vulgaris

  • Apply TOPICALLY in concentrations of 0.5% to 10%

Disorder of skin, Hyperkeratotic: gel, apply TOPICALLY to the affected area and occlude the area at night.

  • Disorder of skin, Hyperkeratotic
  • shampoo, wet hair and apply TOPICALLY to the scalp, work into a lather and rinse; repeat the treatment as needed until the condition clears [5]
  • Psoriasis
  • Apply TOPICALLY in concentrations of 3% to 6%
  • Removal of wart
  • Apply TOPICALLY once or twice daily in concentrations of 5% to 40% for up to 12 weeks

|offLabelAdultNoGuideSupport=


There is limited information regarding Off-Label Non–Guideline-Supported Use of Salicylic acid in adult patients.


|fdaLIADPed=


There is limited information regarding FDA-Labeled Use of Salicylic acid in pediatric patients.


|offLabelPedGuideSupport= There is limited information regarding Off-Label Guideline-Supported Use of Salicylic acid in pediatric patients.

|offLabelPedNoGuideSupport= There is limited information regarding Off-Label Non–Guideline-Supported Use of Salicylic acid in pediatric patients.

|warnings=* For external use only.

  • Avoid contact with eyes. If contact occurs, rinse thoroughly with water.
  • Do not use without consulting a doctor if the condition appears over a large portion of hte body.
  • If condition worsens, or does not improve after using as directed, consult physician.
  • Do not use for prolonged periods without consulting a doctor.

|clinicalTrials=There is limited information regarding Clinical Trial Experience of Salicylic acid in the drug label. |postmarketing=There is limited information regarding Postmarketing Experience of Salicylic acid in the drug label. |useInPregnancyFDA=* Pregnancy Category |useInPregnancyAUS=* Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Salicylic acid in women who are pregnant. |useInLaborDelivery=There is no FDA guidance on use of Salicylic acid during labor and delivery. |useInNursing=There is no FDA guidance on the use of Salicylic acid with respect to nursing mothers. |useInPed=There is no FDA guidance on the use of Salicylic acid with respect to pediatric patients. |useInGeri=There is no FDA guidance on the use of Salicylic acid with respect to geriatric patients. |useInGender=There is no FDA guidance on the use of Salicylic acid with respect to specific gender populations. |useInRace=There is no FDA guidance on the use of Salicylic acid with respect to specific racial populations. |useInRenalImpair=There is no FDA guidance on the use of Salicylic acid in patients with renal impairment. |useInHepaticImpair=There is no FDA guidance on the use of Salicylic acid in patients with hepatic impairment. |useInReproPotential=There is no FDA guidance on the use of Salicylic acid in women of reproductive potentials and males. |useInImmunocomp=There is no FDA guidance one the use of Salicylic acid in patients who are immunocompromised.

|administration=* Oral


|monitoring=There is limited information regarding Monitoring of Salicylic acid in the drug label.


|IVCompat=There is limited information regarding IV Compatibility of Salicylic acid in the drug label.

|overdose=There is limited information regarding Chronic Overdose of Salicylic acid in the drug label.


|drugBox=

Template:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox ECNumberTemplate:Chembox E numberTemplate:Chembox RTECSTemplate:Chembox AppearanceTemplate:Chembox OdourTemplate:Chembox DensityTemplate:Chembox MeltingPtTemplate:Chembox BoilingPtTemplate:Chembox SublimationConditionsTemplate:Chembox SolubilityInWaterTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox SolubilityTemplate:Chembox LogPTemplate:Chembox VaporPressureTemplate:Chembox pKaTemplate:Chembox LambdaMaxTemplate:Chembox RefractIndexTemplate:Chembox Supplement
Template:Chembox header2 | Salicylic acid
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
KEGG
UNII
Properties
C7H6O3
Molar mass 138.12 g·mol−1
Template:Chembox header2 | Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references

{{#subobject: 

 |Label Page=Salicylic acid
 |Label Name=Saly 1.jpg

}}

{{#subobject: 

 |Label Page=Salicylic acid
 |Label Name=

}}

  1. ↑ 1.0 1.1 1.2 Template:RubberBible92nd
  2. ↑ 2.0 2.1 2.2 Template:PubChemLink
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 http://chemister.ru/Database/properties-en.php?dbid=1&id=1777
  4. ↑ 4.0 4.1 4.2 Seidell, Atherton; Linke, William F. (1952). [Google Books Solubilities of Inorganic and Organic Compounds] Check |url= value (help). Van Nostrand. Retrieved 2014-05-29.
  5. ↑ Salicyclic acid. Drugbank.ca. Retrieved on 2012-06-03.
Retrieved from "https://www.wikidoc.org/index.php?title=Salicylic_acid&oldid=1048692"